OcuMedics

OcuMedics is a clinical-stage biotechnology company developing a transformative drug delivery platform for the treatment of ocular diseases. The company's core technology involves the use of molecularly imprinted polymers (MIP) within contact lenses to enable the sustained and controlled release of therapeutics to the eye. This drug-device combination is designed to overcome the limitations of traditional eye drops, such as low bioavailability and poor patient adherence. OcuMedics is currently advancing programs for indications including allergic conjunctivitis and glaucoma. The company's innovative approach seeks to provide a more effective and convenient treatment modality for millions of patients worldwide.